Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Dudek, D.
Right arrow Articles by Dubiel, J. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dudek, D.
Right arrow Articles by Dubiel, J. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight)

Dariusz Dudek1,2,*, Artur Dziewierz2, Bernadeta Chyrchel2, Lech Polonski3, Jacek Legutko2 and Jacek S. Dubiel2

1 Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Kopernika 17, 31-501 Krakow, Poland
2 2nd Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Kopernika 17, 31-501 Krakow, Poland
3 Department of Cardiology, Silesian Center for Heart Diseases, Szpitalna 2, 41-800 Zabrze, Poland

* Corresponding author. Tel: +48 12 424 71 81; fax: +48 12 424 71 84. E-mail address: mcdudek{at}cyf-kr.edu.pl

Non-ST-segment elevation acute coronary syndrome (NSTEACS) is the leading cause of hospital admission for ischaemic heart disease. Despite major progress in diagnosis and treatment, NSTEACS remains to be associated with poor short- and long-term prognoses. For this reason, it appears reasonable to follow the guidelines of the European Society of Cardiology and recommend optimal and intensive pharmacotherapy including antiplatelet agents and invasive cardiac procedures, especially in NSTEACS patients at high risk of death and/or myocardial infarction. Aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors are the most frequent antiplatelet agents used for the treatment of NSTEACS. This article summarizes current recommendations for use those agents in NSTEACS treatment.

Key Words: Non-ST-elevation • Acute coronary syndromes • Pharmacotherapy • Clopidogrel • GPIIb/IIIa inhibitors • Antithrombotic therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.